Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Theradiag
  6. News
  7. Summary
    ALTER   FR0004197747

THERADIAG

(ALTER)
  Report
Real-time Euronext Paris  -  11:00:18 2023-03-31 am EDT
2.145 EUR   -.--%
03/01Theradiag SA Announces Executive Changes
CI
03/01Theradiag SA Announces Management Changes
CI
01/31Biosynex SA (ENXTPA:ALBIO) completed the acquisition of additional 46.52% stake in Theradiag SA (ENXTPA:ALTER) for €21.6 million.
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Theradiag : enhances its oncology offer, with an 8th test in its Lisa-Tracker theranostic range: Avastin« test received CE marking (08 / 07 / 2014 )

07/21/2014 | 10:56am EDT
THERADIAG enhances its oncology offer, with an 8th test in its Lisa-Tracker theranostic range: Avastin® test received CE marking

Croissy-Beaubourg and Montpellier, 8 July 2014 - THERADIAG (ISIN: FR0004197747, Ticker: ALTER, PEA-PME eligible), a company specializing in in-vitro diagnostics and theranostics, today announces that its Lisa-Tracker range has been further expanded, with an 8th test receiving CE marking in oncology.
With the monitoring of the drug and of the anti-drug antibodies, this new test could optimize the treatment of patients on Avastin® (bevacizumab molecule). Avastin® is the only anti-angiogenic 1 therapy available for treating patients with advanced breast, colon, lung, kidney or ovarian cancer, which are responsible for more than 2.5 million deaths every year.
This kit, developed by Theradiag, is the Lisa-Tracker range's second test in oncology and will soon be marketed worldwide. It meets a major need from practitioners, with more than a million patients currently being treated with Avastin®. In 2013, sales of this drug totaled approximately 6.7 billion dollars (+8% compared with 2012). Furthermore, a vast program of more than 500 clinical trials is also currently underway and is looking into the possible use of Avastin® in around fifty additional types of tumor.

Michel Finance, CEO of THERADIAG, comments: "This 8th CE marked test is further proof of our commitment and our expertise in the development of the Lisa-Tracker range and our activity in theranostics. It enables us to expand our range and our activity to oncology. Further developments are ongoing, and will result in additional CE markings in 2014."

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of HIV/AIDS and rectal cancer. Theradiag is thus participating in the development of "customized treatment", which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-
Vallée, near Paris, and in Montpellier, and has over 60 employees.

1 Anti-angiogenic treatment: the use of drugs to inhibit angiogenesis, i.e. the production of blood vessels that irrigate cancerous tumors. The tumors, thus starved of blood, gradually disappear.

1/2

Theradiag

Investor Relations

Nathalie Trepo

Phone: +33 1 64 62 10 12

ntrepo@theradiag.com

NewCap.

Financial communications/

investor relations Valentine Brouchot / Pierre Laurent

Phone: +33 1 44 71 94 94 theradiag@newcap.fr

Alize RP

Press

Caroline Carmagnol theradiag@alizerp.com Phone: +33 6 64 18 99 59

2/2

distributed by

ę Publicnow 2014
All news about THERADIAG
03/01Theradiag SA Announces Executive Changes
CI
03/01Theradiag SA Announces Management Changes
CI
01/31Biosynex SA (ENXTPA:ALBIO) completed the acquisition of additional 4..
CI
01/16Theradiag : Inside Information / News release on accounts, results
PU
01/16Theradiag SA Announces Revenue Results for the Year Ended December 31, 2022
CI
01/12Biosynex SA (ENXTPA:ALBIO) completed the acquisition of 40% stakes i..
CI
01/06Theradiag : Inside Information / Other news releases
PU
2022Theradiag : News releases during takeover bids / Takeover bids Other news releases
PU
2022French Diagnostics Company Biosynex Offers to Take Over Theradiag
MT
2022Biosynex SA (ENXTPA:ALBIO) bid to acquire remaining 74.93% stakes in..
CI
More news
Financials
Sales 2022 12,5 M 13,6 M 13,6 M
Net income 2022 - - -
Net cash 2022 3,40 M 3,69 M 3,69 M
P/E ratio 2022 -
Yield 2022 -
Capitalization 27,9 M 30,3 M 30,3 M
EV / Sales 2022 1,96x
EV / Sales 2023 1,88x
Nbr of Employees 60
Free-Float 51,8%
Chart THERADIAG
Duration : Period :
Theradiag Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERADIAG
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 2,15 €
Average target price 2,20 €
Spread / Average Target 2,56%
EPS Revisions
Managers and Directors
Bertrand Michel Marle de Castelnau Chief Executive Officer & Managing Director
Muriel Bardet Chief Financial Officer
Christian Policard Chairman
Jacques Azancot Independent Director
Larry Abensur Director
Sector and Competitors
1st jan.Capi. (M$)
THERADIAG-5.92%30
MODERNA, INC.-14.50%59 232
LONZA GROUP AG20.81%44 555
SEAGEN INC.57.55%37 885
IQVIA HOLDINGS INC.-2.93%36 938
ALNYLAM PHARMACEUTICALS, INC.-15.71%24 866
MarketScreener: Created by Investors for Investors!
100% Free Registration
fermer